Neurocrine Biosciences
NBIX
#1407
Rank
S$20.45 B
Marketcap
S$203.44
Share price
-1.41%
Change (1 day)
32.10%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2026 (TTM): S$1.02 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are S$3.10 Billion. In 2025 the company made an earning of S$0.81 Billion, an increase over its 2024 earnings that were of S$0.78 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) S$1.02 B25.93%
2025 S$0.81 B3.9%
2024 S$0.78 B96.41%
2023 S$0.39 B41.13%
2022 S$0.28 B73.74%
2021 S$0.16 B-8.82%
2020 S$0.17 B77.78%
2019 S$0.10 B49.83%
2018 S$66.98 M-142.57%
2017 -S$0.16 Billion-14.73%
2016 -S$0.19 Billion53.15%
2015 -S$0.13 Billion46.25%
2014 -S$82.39 Million29.66%
2013 -S$63.55 Million-3530.8%
2012 S$1.85 M-95.73%
2011 S$43.39 M
2009 -S$61 Million-45.38%
2008 -S$0.12 Billion-58.87%
2007 -S$0.28 Billion87.3%
2006 -S$0.15 Billion351.97%
2005 -S$32.08 Million-52.09%
2004 -S$66.95 Million-10.98%
2003 -S$75.2 Million
2001 -S$56.14 Million
1999 -S$25.32 Million108.32%
1998 -S$12.16 Million
1996 S$3.7 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
S$13.54 B 1,225.86%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$8.43 B 725.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$39.81 B 3,796.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S$0.10 B-89.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-S$53.42 Million-105.23%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$0.12 B-88.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-S$6.14 Million-100.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.16 B 112.21%๐Ÿ‡ฌ๐Ÿ‡ง UK